104 related articles for article (PubMed ID: 20647567)
1. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
2. Reversal of glucocorticoid resistance in paediatric acute lymphoblastic leukaemia is dependent on restoring BIM expression.
Toscan CE; Jing D; Mayoh C; Lock RB
Br J Cancer; 2020 Jun; 122(12):1769-1781. PubMed ID: 32242100
[TBL] [Abstract][Full Text] [Related]
3. Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model.
Jones CL; Bhatla T; Blum R; Wang J; Paugh SW; Wen X; Bourgeois W; Bitterman DS; Raetz EA; Morrison DJ; Teachey DT; Evans WE; Garabedian MJ; Carroll WL
J Biol Chem; 2014 Jul; 289(30):20502-15. PubMed ID: 24895125
[TBL] [Abstract][Full Text] [Related]
4. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Cang S; Ma Y; Liu D
J Hematol Oncol; 2009 Jun; 2():22. PubMed ID: 19486511
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lindemann RK; Newbold A; Whitecross KF; Cluse LA; Frew AJ; Ellis L; Williams S; Wiegmans AP; Dear AE; Scott CL; Pellegrini M; Wei A; Richon VM; Marks PA; Lowe SW; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2007 May; 104(19):8071-6. PubMed ID: 17470784
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM.
Matheson EC; Thomas H; Case M; Blair H; Jackson RK; Masic D; Veal G; Halsey C; Newell DR; Vormoor J; Irving JAE
Haematologica; 2019 Sep; 104(9):1804-1811. PubMed ID: 30655370
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
Quagliano A; Gopalakrishnapillai A; Barwe SP
Leuk Res; 2017 May; 56():36-43. PubMed ID: 28171800
[TBL] [Abstract][Full Text] [Related]
8. ESRRB regulates glucocorticoid gene expression in mice and patients with acute lymphoblastic leukemia.
Gallagher KM; Roderick JE; Tan SH; Tan TK; Murphy L; Yu J; Li R; O'Connor KW; Zhu J; Green MR; Sanda T; Kelliher MA
Blood Adv; 2020 Jul; 4(13):3154-3168. PubMed ID: 32658986
[TBL] [Abstract][Full Text] [Related]
9. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
10. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia.
Autry RJ; Paugh SW; Carter R; Shi L; Liu J; Ferguson DC; Lau CE; Bonten EJ; Yang W; McCorkle JR; Beard JA; Panetta JC; Diedrich JD; Crews KR; Pei D; Coke CJ; Natarajan S; Khatamian A; Karol SE; Lopez-Lopez E; Diouf B; Smith C; Gocho Y; Hagiwara K; Roberts KG; Pounds S; Kornblau SM; Stock W; Paietta EM; Litzow MR; Inaba H; Mullighan CG; Jeha S; Pui CH; Cheng C; Savic D; Yu J; Gawad C; Relling MV; Yang JJ; Evans WE
Nat Cancer; 2020 Mar; 1(3):329-344. PubMed ID: 32885175
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibition sensitizes p53-deficient B-cell precursor acute lymphoblastic leukemia to chemotherapy.
Cox WPJ; Evander N; Van Ingen Schenau DS; Stoll GR; Anderson N; De Groot L; Grünewald KJT; Hagelaar R; Butler M; Kuiper RP; Van der Meer LT; Van Leeuwen FN
Haematologica; 2024 Jun; 109(6):1755-1765. PubMed ID: 38124624
[TBL] [Abstract][Full Text] [Related]
12. CD9 shapes glucocorticoid sensitivity in pediatric B-cell precursor acute lymphoblastic leukemia.
Zhang C; Chan KYY; Ng WH; Cheung JTK; Sun Q; Wang H; Chung PY; Cheng FWT; Leung AWK; Zhang XB; Lee PY; Fok SP; Lin G; Poon ENY; Feng JH; Tang YL; Luo XQ; Huang LB; Kang W; Tang PMK; Huang J; Chen C; Dong J; Mejstrikova E; Cai J; Liu Y; Shen S; Yang JJ; Yuen PMP; Li CK; Leung KT
Haematologica; 2024 Apr; ():. PubMed ID: 38572553
[TBL] [Abstract][Full Text] [Related]
13. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia.
Chang Y; Keramatnia F; Ghate PS; Nishiguchi G; Gao Q; Iacobucci I; Yang L; Chepyala D; Mishra A; High AA; Goto H; Akahane K; Peng J; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2023 Aug; 142(7):629-642. PubMed ID: 37172201
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation as a pharmacodynamic marker of glucocorticoid response and glioma survival.
Wiencke JK; Molinaro AM; Warrier G; Rice T; Clarke J; Taylor JW; Wrensch M; Hansen H; McCoy L; Tang E; Tamaki SJ; Tamaki CM; Nissen E; Bracci P; Salas LA; Koestler DC; Christensen BC; Zhang Z; Kelsey KT
Nat Commun; 2022 Sep; 13(1):5505. PubMed ID: 36127421
[TBL] [Abstract][Full Text] [Related]
15. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.
Jing D; Bhadri VA; Beck D; Thoms JA; Yakob NA; Wong JW; Knezevic K; Pimanda JE; Lock RB
Blood; 2015 Jan; 125(2):273-83. PubMed ID: 25336632
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.
Piazza R; Magistroni V; Mogavero A; Andreoni F; Ambrogio C; Chiarle R; Mologni L; Bachmann PS; Lock RB; Collini P; Pelosi G; Gambacorti-Passerini C
Neoplasia; 2013 May; 15(5):511-22. PubMed ID: 23633923
[TBL] [Abstract][Full Text] [Related]
17. Chemo-free maintenance therapy in adult T-cell acute lymphoblastic leukemia: A case report and literature review.
Song Y; Chen S; Liu C; Chen L; Wang W; Wu B; Liang Y
Front Pharmacol; 2023; 14():1051305. PubMed ID: 36873995
[TBL] [Abstract][Full Text] [Related]
18. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
19. The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.
Meyer LK; Hermiston ML
Cancer Drug Resist; 2019; 2(2):313-325. PubMed ID: 35582725
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies.
Scheijen B
Cancer Drug Resist; 2019; 2(3):647-664. PubMed ID: 35582582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
